Crescent Biopharma, Inc.

NASDAQ:CBIO

Biotechnology

Healthcare
$12.40 -2.69%

-$0.49 today

Market cap
$482.30M
Beta
1.15
P/E (TTM)
-3.3
EPS (TTM)
-$5.33
52W Low $8.72High $27.41

Volume 0.33M

Average 0.28M

Balance Sheet

Inspect the capital base behind the business.

Assets

$240.29M

FY 2025 · Annual

+574.7% YoY

Liabilities

$37.28M

FY 2025 · Annual

-27.0% YoY

Equity

$203.01M

FY 2025 · Annual

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents90.25M47.87M41.79M34.77M213.19M
Short-term Investments00000
Net Receivables1.35K144.02K175.82K018M
Inventory00000
Other Current Assets00038K1.28M
Total Current Assets90.79M50.71M43.79M34.8M236.66M
Property, Plant & Equipment (Net)1.95M751.17K767.83K02.32M
Goodwill00000
Intangible Assets00004.73M
Long-term Investments0000107K
Tax Assets00000
Other Non-current Assets1.61M344.71K757.91K813K(3.51M)
Total Non-current Assets3.56M1.1M1.53M813K3.64M
Total Assets94.35M51.81M45.32M35.62M240.29M
Account Payables2.11M970.19K868.12K107K10M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00004.16M
Other Current Liabilities2.5M2.97M2.96M76K16.36M
Total Current Liabilities11.82M8.88M6.84M9.61M36.07M
Long-term Debt00037.48M0
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities0004M0
Total Non-current Liabilities918.61K066.84K41.48M1.21M
Total Liabilities12.74M8.88M6.9M51.1M37.28M
Common Stock52.31K54.38K64.39K1K28K
Retained Earnings(372.9M)(419.59M)(456.49M)(17.87M)(171.81M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity81.6M42.93M38.41M(15.48M)203.01M
Total Debt1.92M918.56K808.4K37.48M1.64M
Net Debt(88.33M)(46.95M)(40.98M)2.72M(211.55M)

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$189.2M
Other Current$6.4M
Total Current Assets$195.6M
PP&E (Net)$2.3M
Intangible Assets$4.6M
Long-term Investments$107.0K
Other Non-current-$3.5M
Total Non-current Assets$3.6M
Total Assets$199.1M

Analysis

Selected assets total $199.1M for Latest. The largest visible component is Cash & Equivalents at $189.2M, about 95.0% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 12, 2026
10-QQuarterly reportNov 12, 2026
SC 13GSC 13G filingOct 27, 2026
8-KCurrent reportOct 15, 2026
4Statement of changes in beneficial ownershipSep 18, 2026

How much cash does CBIO have?

Crescent Biopharma, Inc. (CBIO) reported $213.19M in cash and equivalents in fiscal 2025.

How much debt does CBIO carry?

Crescent Biopharma, Inc. (CBIO) reported $1.64M of total debt, with net debt of -$211.55M.